Introduction
============

Malignant melanoma (MM) is one of the most common types of cancer in humans, being the fifth most common in men and the sixth in women in the United States \[[@b1-dp0901a013]\]. Although MM represents less than 2% of skin cancer, it accounts for the vast majority of deaths, with increasing incidence worldwide \[[@b1-dp0901a013]\]. The underlying etiopathogenetic mechanisms remain so far largely unknown.

Following discovery of *BRAF* oncogenic mutations in various types of malignancies, a significant pathogenetic role for mutated *BRAF* has been proposed for MM \[[@b2-dp0901a013]\]. To date, more than 30 different mutations in the *BRAF* gene have been identified. The most frequent, accounting for almost 90%, concerns substitution of thymine by adenine at nucleotide c.1799, leading to valine (V) being substituted by glutamate (E) at codon 600 (p.V600E) in the activation segment of the gene promoting cell survival via the *ERK* or *MEK* signaling cascade \[[@b3-dp0901a013]\]. Frequency of *BRAF* mutations varies widely, from more than 80% in melanomas and nevi, to 1%--3% in lung and 5% in colorectal carcinoma \[[@b2-dp0901a013]\]. Of note, *BRAF* mutations are not exclusive to MM, having also been found in up to 80% of benign melanocytic lesions, albeit in limited study populations \[[@b4-dp0901a013]\].

Oncogenic mutations of *BRAF* are mimicking a constantly activated state, resulting in uncontrolled cell growth and proliferation. More recently, oncogenic *BRAF* mutations have been connected to up-regulated cell proliferation and invasion ability \[[@b5-dp0901a013]\]. It has been suggested that *BRAF* mutations may constitute a tumor progression event rather than an initiating event in MM tumorigenesis, and that other genetic or epigenetic factors are also involved \[[@b6-dp0901a013], [@b7-dp0901a013]\]. The presence of a *BRAF* mutation in primary MM of stage III has been associated with worse prognosis and also seems to be related to progression-free interval and overall survival \[[@b8-dp0901a013]\].

Mutated *BRAF* constitutes a therapeutic target for patients with advanced MMs. Different *BRAF* inhibitors have been tested, with significant benefits in terms of increased response rate, progression-free survival, and overall survival \[[@b9-dp0901a013]\]. Nevertheless, the prognostic value of *BRAF* mutations has not been fully assessed, with the only established histopathological parameters associated with prognosis and survival of MMs being tumor thickness, ulceration, and, more recently, mitotic score at primary site \[[@b10-dp0901a013]\].

We assessed the *BRAF* mutation status among 178 patients with primary, recurrent, or metastatic MM. Our aim was to study the correlations between histopathological findings in primary MM and the presence of mutated *BRAF* in a Greek population.

Methods
=======

Specimens
---------

A total of 203 consecutive specimens from 178 patients referred for histopathological examination during a 12-year period (2003--2015) were analyzed ([Table 1](#t1-dp0901a013){ref-type="table"}). These included 129 primary cutaneous MMs (a primary site recurrence was also included in 13 cases and a metastasis in 12 cases), 44 cases of metastatic MM of unknown primary site, and 5 cases of cutaneous recurrence without an initial tumor. The institutional review board of the hospital approved the study, while analysis was performed on anonymized data.

All specimens were fixed in a buffered 10% formalin solution, processed according to standard protocols, and initially diagnosed by the same experienced pathologist. Another, equally experienced pathologist performed a second, blind evaluation of histopathological diagnosis for the purpose of this study. In case of disagreement, slides were conjointly rereviewed.

*BRAF* Mutation Analysis
------------------------

Five 5-μm-thick sections were obtained from a paraffin block containing a representative tumor area, as assessed in a hematoxylin and eosin--stained section. DNA was extracted with Purelink DNA Mini KIT (Invitrogen, Darmstadt, Germany) according to the manufacturer's instructions. Detection of *BRAF* p.V600E mutation was performed with the use of 2 molecular beacons in a real-time polymerase chain reaction as previously described \[[@b11-dp0901a013]\]. All wild-type and selected mutated samples were sent for verification with direct sequencing of exon 15 of *BRAF* using previously published primers or were sequenced in-house using a commercially available kit (Therascreen BRAF pyro kit, Qiagen, Düsseldorf, Germany) \[[@b11-dp0901a013]\].

Primers and Beacons
-------------------

*BRAF* primers and molecular beacons were designed with Beacon Designer 7 (Premier Biosoft, Palo Alto, CA). Oligos were synthesized by Jena Bioscience GmbH (Jena, Germany).

Quality Assurance
-----------------

Both the Department of Cytopathology and the second Department of Pathology have successfully participated in the European Quality Assurance schemes of the European Society of Pathology for molecular identification of mutations in *KRAS, NRAS*, and *BRAF* since 2013 and through 2016.

Statistical Analysis
--------------------

Statistical analysis was performed using IBM Statistics SPSS 24 (IBM Corporation, New York, NY) and involved the Fisher exact test for 2 × 2 tables, χ^2^ for trend for 2 × Y tables, Mann-Whitney test for differences of mean of categories, and Spearman correlation analysis for scale correlations. Binary logistic regression was used for validation of observed differences of *BRAF* status with all mutations grouped in a single category.

Results
=======

Demographic and Clinical Data
-----------------------------

One hundred seventy-eight melanoma patients aged 21--95 years (mean 62.1 years) were included in the study. There were 105 men with a mean age of 62.4 years and 73 women with a mean age of 61.4 years. Received samples were monitored to identify repeated samples from the same patients for an average of 70 months (range 1--162 months). Recurrent samples were received within 1 to 32 months (mean 8.5 months), while reported metastases were collected within 0 to 49 months (mean 11.9 months). Metastases were identified in lymph nodes (31/56), gastrointestinal tract (6/56), bone marrow (1/56), lung (1/56), ovaries (2/56), liver (7/56), and skin sites distant from the initial tumor area (8/56). All 18 recurrent specimens concerned cutaneous tumors.

BRAF Mutation Distribution
--------------------------

*BRAF* mutations were identified in a total of 92/203 samples (45.3%). Analyzing only unique samples, *BRAF* mutations were identified in 75/178 samples (42.1%). Of these 75 samples, 63 (84%) carried the V600E mutation (c.1799T\>A), 10 samples (13.3%) the V600K mutation (c.1799_1800TG\>AA), 1 sample (1.3%) carried the V600R mutation (c.1798_1799GT\>AG), and 1 sample (1.3%) the V600A (c.1799T\>C) mutation. The V600K, V600R, and V600A mutations were identified by sequencing only, since the molecular beacons, as expected, could not identify them ([Figures 1](#f1-dp0901a013){ref-type="fig"} and [2](#f2-dp0901a013){ref-type="fig"}).

In 12 patients, samples from both primary site and metastasis were available: in 10/12 (83.3%) cases both sites had the same genotype, whereas one primary carried a V600E mutation not identified in nodal metastasis, and another was WT in the primary with a V600E mutation in the visceral metastasis.

Correlation of *BRAF* Status to Epidemiological and Clinical Parameters
-----------------------------------------------------------------------

Correlation of *BRAF* mutation status with epidemiological and clinical parameters is shown in [Table 1](#t1-dp0901a013){ref-type="table"}. Results for primary and metastatic MMs are shown in [Tables 2](#t2-dp0901a013){ref-type="table"} and [3](#t3-dp0901a013){ref-type="table"}, respectively. Briefly, *BRAF* mutations were more common among younger patients (P = 0.011, Mann-Whitney U test), while the same trend was present for primary and metastatic samples, however without reaching statistical significance. Primary MMs of the torso showed a slightly increased mutation frequency, compared with those located at the extremities or head and neck area (40.3% vs 36.3%, P = 0.269, Fisher exact test). Cutaneous and lymph node metastases also displayed higher mutation frequency, again without reaching statistical significance (53.8% vs 35.2, P = 0.143, Fisher exact test). Mutations were more common in men, although this was statistically significant only in metastatic samples (P = 0.029, Fisher exact test).

Patients with a recurrent melanoma had higher mutation frequency (13/18 vs 41/116, P = 0.004, Fisher exact test), although limited samples were available. Patients with melanoma metastasis showed a slightly increased frequency of *BRAF* mutations (37% vs 30.7%, P = 0.413, Fisher exact test), without reaching statistical significance. These results are only indicative because we analyzed reported metastases and recurrences that had been referred to our laboratory.

Association of BRAF Status to Histopathological Parameters
----------------------------------------------------------

In primary MMs ([Table 4](#t4-dp0901a013){ref-type="table"}), mutated *BRAF* was significantly more common in ulcerated tumors (51.7% vs 31%, P = 0.002, Fisher exact test) or when the adjacent dermis lacked solar elastosis (44.3% vs 7.1%, P = 0.008, Fisher exact test). In contrast, the number of mitoses, presence of tumor-infiltrating lymphocytes (TILs), Clark level, or Breslow thickness were not significantly related to *BRAF* mutation status, apart from a slight increase in *BRAF* mutations among cases with TILs (42.9% vs 37.5%, Fisher exact test) or MMs with Breslow thickness \>1 mm (43.9% vs 38.1%, Fisher exact test).

Concerning the type of MM, mutations were more common in superficial spreading MM (SSM) and nodular MM (NM) and less common in acral lentiginous MM (ALM) and lentigo maligna melanomas (LMM). Primary dermal MM and intraepidermal (in situ) melanomas displayed an intermediate frequency. The trend was significant when analyzing the different types, whether primary dermal and in situ melanomas were included in the analysis or not. Cross-tabulation of melanoma types with *BRAF* status divided by presence of ulceration showed similar mutated samples with or without ulceration for ALM (1/4 vs 0/4), LMM (1/5 vs 1/7), and SMM (10/16 vs 13/27), but not for NM (2/14 vs 18/32, 14.3% vs 56.2%, P = 0.010, Fisher exact test).

We then used a backward step-wise Wald binary logistic regression analysis including all borderline and statistically significant parameters. Topology and age were removed during model creation, while ulceration (P = 0.008, odds ratio = 3.509) and type (P = 0.024), specifically SSM type (P = 0.020, odds ratio = 7.626), were the only predictors.

Discussion
==========

Per our results, a 42.1% prevalence of *BRAF* mutations at codon 600 among our patients with MM was observed. These mutations were statistically more common in younger patients, in ulcerated MMs, and in MMs lacking solar elastosis in adjacent papillary dermis. These findings are consistent with previous experience \[[@b7-dp0901a013], [@b12-dp0901a013]\]. A trend for increased percentage of *BRAF* mutations was documented in men with MMs of the torso, in MMs more than 1 mm Breslow thickness, higher mitotic rate, reported metastasis, and earlier reported recurrences. However, these findings did not reach statistical significance, as some of them did in previous studies \[[@b12-dp0901a013], [@b13-dp0901a013]\]. Almost all pairs of primary and metastatic sites had the same genotype, except 2 patients, in whom a discordance of *BRAF* status between primary site and metastasis was found \[[@b7-dp0901a013], [@b14-dp0901a013]\].

In a recent meta-analysis, *BRAF* and *NRAS* mutations were associated with histological subtype and tumor site, but not with patient age or sex \[[@b15-dp0901a013]\]. *BRAF* mutations were frequently detected in patients with SSM and in MMs arising in non--chronically sun-damaged skin. In contrast, *NRAS* mutations were more frequent in patients with NM and in MMs arising in chronically sun-damaged skin \[[@b15-dp0901a013]\]. Another meta-analysis of *BRAF* mutations and their associations with the clinicopathological characteristics of primary MM showed an association of *BRAF* mutations with younger age, location at the torso, non--chronically sun-damaged skin, SSM type, and advanced melanoma stage \[[@b16-dp0901a013]\]. Similar results were identified in our sample set, but after using a logistic regression model, only ulceration and melanoma type were significant predictors.

In agreement with previous studies, *BRAF* mutations were more commonly found in SSM, and with decreasing frequency in NM, ALM, and LMM \[[@b12-dp0901a013], [@b13-dp0901a013], [@b16-dp0901a013], [@b17-dp0901a013]\]. As expected, intraepidermal (in situ) MMs had an intermediate *BRAF* mutation frequency. Upon further analysis, we identified that ulcerated NMs had a *BRAF* mutation frequency similar to SSMs (56.4%), whereas non-ulcerated NMs had a percentage more akin to that of the ALM/LMM group (14.3%). This could be explained if one considers ulcerated NMs as rapidly growing ex-SSMs, whose adjacent intraepidermal component was phased out \[[@b18-dp0901a013]\].

Another histopathological parameter significantly related to *BRAF* mutations was ulceration. Some studies have also reported increased *BRAF* mutation percentage in ulcerated samples \[[@b12-dp0901a013], [@b17-dp0901a013], [@b19-dp0901a013]--[@b21-dp0901a013]\], while others, including a meta-analysis, did not \[[@b13-dp0901a013], [@b16-dp0901a013]\]. The 2 studies that included only 1 type of melanoma (NM) identified a clear correlation \[[@b20-dp0901a013], [@b21-dp0901a013]\]. Furthermore, we identified increased mitotic rate in ulcerated melanomas (8.71 vs 2.21, P \< 0.001, Mann-Whitney test), yet no correlation between an increased mitotic rate and *BRAF* mutation percentage was identified (4.8 vs 5.6, P = 0.307, Mann-Whitney test). This seems contradictory, since ulceration has been correlated with *BRAF* mutations \[[@b12-dp0901a013], [@b17-dp0901a013], [@b19-dp0901a013]\] and increased mitotic rate \[[@b20-dp0901a013], [@b22-dp0901a013]\]. Upon further analysis, lower mitotic rates were found in mutated tumors compared with wild-type ones (2.2 vs 6.83) in ALM, LMM, and non-ulcerated NM, whereas the contrary was true concerning ulcerated NM and SSM (6.80 vs 4.82).

*BRAF* mutations have been previously linked to transition from radial to vertical growth phase \[[@b6-dp0901a013], [@b23-dp0901a013]\]; to shorter recurrence-free, disease-specific survival \[[@b8-dp0901a013]\]; and to overall survival with a more protracted growth rate \[[@b24-dp0901a013]\]. However, the exact role and the pathways mirrored in specific morphological features such as ulceration and pathology types is elusive.

Conclusions
-----------

Our results suggest that *BRAF* mutations are more frequent in SSM, ulcerated MMs independent of histological type, and MMs arising in non--chronically sun-damaged skin, ie, lacking solar elastosis. A significantly higher number of cases is required to clarify whether these correlations identified by many studies, as well as ours, are influenced by the variance of different populations, ages, and melanoma types included in each study. *BRAF*-mutated melanoma patients already have the advantage of being more effectively treated with drugs that specifically target *BRAF*-mutated cells, a fact that may mask the potential contribution of mutation presence to metastasis development. Furthermore, as both new immune-related therapies and driver mutations for development and metastasis of MM are further identified, molecular profile of MMs may contribute to distinguishing melanoma types and estimating prognosis more accurately \[[@b25-dp0901a013]\].
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Real-time polymerase chain reaction plots of serial dilutions depicting that even rare mutation-harboring populations be identified using molecular beacons (red-colored line = mutant; green-colored line = wild type). \[Copyright: ©2019 Spathis et al.\] \[Copyright: ©2019 Spathis et al.\]
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###### 

Sample Types and *BRAF* Status

                                 *BRAF* Status       Total               Mutated (%)         P      
  ------------------------------ ------------------- ------------------- ------------------- ------ -------
  Patients                       103                 75                  178                 42.1   
  Sample type                    111                 92                  203                 45.3   
   Primary melanoma              77                  52                  129                 40.3   0.300
   Metastasis of primary         6                   6                   12                  50.0   
   Metastasis w/o primary        23                  21                  44                  47.7   
   Recurrence of primary         2                   11                  13                  84.6   
   Recurrence w/o primary        3                   2                   5                   40.0   
  Age, mean (95% CI) (n = 178)   64.6 (61.5--67.6)   58.9 (55.6--62.2)   62.1 (59.9--64.4)          0.011
  Sex (n = 178)                                                                                     
   Male                          55                  50                  105                 47.6   0.090
   Female                        48                  25                  73                  34.2   

CI = confidence interval; WT = wild type.

###### 

Patient Characteristics of Primary Melanomas and *BRAF* Status

                                 *BRAF* Status       Total               Mutated (%)         P      
  ------------------------------ ------------------- ------------------- ------------------- ------ -------
  Age, mean (95% CI) (n = 129)   65.3 (61.8--68.7)   60.2 (56.1--64.3)   63.2 (60.5--65.8)          0.086
  Sex (n = 129)                                                                                     
   Male                          43                  35                  78                  44.9   0.205
   Female                        34                  17                  51                  33.3   
  Primary site (n = 129)                                                                            
   Head and neck                 17                  9                   26                  34.6   0.254
   Extremities                   34                  20                  54                  37.0   
   Torso                         26                  23                  49                  40.3   

CI = confidence interval; WT = wild type.

###### 

Patient Characteristics of Metastatic Melanomas and *BRAF* Status

                                *BRAF* Status       Total               Mutated (%)         P      
  ----------------------------- ------------------- ------------------- ------------------- ------ -------
  Age, mean (95% CI) (n = 56)   61.5 (55.3--67.7)   57.7 (51.9--63.5)   59.7 (55.5--63.8)          0.251
  Sex (n = 56)                                                                                     
   Male                         14                  21                  35                  60.0   0.029
   Female                       15                  6                   21                  28.6   
  Metastasis site (n = 56)                                                                         
   Distant skin or LN           18                  21                  39                  53.8   0.149
   Lung                         0                   1                   1                   100    
   Other visceral               11                  5                   16                  31.3   

CI = confidence interval; LN = lymph node; WT = wild type

###### 

Histopathological Findings and *BRAF* Status of Primary MM

                                                      *BRAF* Status     Total             Mutated (%)       P      
  --------------------------------------------------- ----------------- ----------------- ----------------- ------ -------
  Type (n = 126)                                                                                                   
   ALM                                                7                 1                 8                 12.5   0.004
   LMM                                                10                2                 12                16.7   
   Primary dermal                                     2                 1                 3                 33.3   
   In situ                                            9                 5                 14                35.7   
   NM                                                 26                20                46                43.5   
   SSM                                                20                23                43                53.5   
  Clark level (n = 121)                               2.68 (2.4--3.0)   2.54 (2.3--2.8)   2.62 (2.4--2.8)          0.741
   1                                                  9                 5                 14                35.7   0.386
   2                                                  31                23                54                42.6   
   3                                                  12                13                25                52.0   
   4                                                  12                8                 20                40.0   
   5                                                  7                 1                 8                 12.5   
  Breslow thickness in mm, (n = 113), mean (95% CI)   3.63 (2.8--4.5)   3.87 (2.6--5.1)   3.73 (4.9--7.8)          0.585
   Breslow thickness ≤1mm                             26                16                42                38.1   0.569
   Breslow thickness \>1mm                            46                36                82                43.9   
   Tis                                                10                6                 16                37.5   0.828
   T1                                                 16                10                25                38.5   
   T2                                                 9                 8                 17                47.1   
   T3                                                 9                 10                19                52.6   
   T4                                                 28                18                46                39.1   
  TILs (n = 109)                                                                                                   
   Absent                                             20                12                32                37.5   0.875
   Nonbrisk                                           32                24                56                42.9   
   Brisk                                              12                9                 21                42.9   
  Mitoses (n = 129), mean (95% CI)                    5.8 (3.8--7.8)    6.74 (4.6--8.8)   6.3 (4.9--7.8)           0.307
   Mitoses \<1/mm2                                    16                9                 25                36.0   0.658
   Mitoses ≥1/mm2                                     61                43                104               41.3   
  Ulceration (n = 129)                                                                                             
   No                                                 49                22                71                31.0   0.020
   Yes                                                28                30                58                51.7   
  Solar elastosis (n = 129)                                                                                        
   No                                                 64                51                115               44.3   0.008
   Yes                                                13                1                 14                7.1    

CI = confidence interval; Tis = Tumor in situ; WT = wild type.
